Neurocrine Biosciences (NBIX) Non-Current Assets (2010 - 2026)

Neurocrine Biosciences' Non-Current Assets history runs 17 years deep, the most recent figure standing at $2.5 billion for Q1 2026.

• Quarterly Non-Current Assets rose 20.5% year-over-year to $2.5 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.8 billion (up 20.3% YoY) and the FY2025 annual result came in at $2.1 billion, up 5.76% from the prior year.
• Non-Current Assets was $2.5 billion for Q1 2026 at Neurocrine Biosciences, up from $2.1 billion in the prior quarter.
• Across five years, Non-Current Assets topped out at $2.5 billion in Q1 2026 and bottomed at $915.2 million in Q4 2022.
• A 5-year average of $1.6 billion and a median of $1.6 billion in 2023 frame the typical range for Non-Current Assets.
• Annual changes were most pronounced in 2023 — Non-Current Assets retreated 17.7% — and 2024, when it jumped 80.52%.
• Neurocrine Biosciences' Non-Current Assets stood at $915.2 million in 2022, then jumped by 79.68% to $1.6 billion in 2023, then grew by 21.26% to $2.0 billion in 2024, then advanced by 5.76% to $2.1 billion in 2025, then increased by 17.13% to $2.5 billion in 2026.
• Business Quant data shows NBIX's Non-Current Assets at $2.5 billion in Q1 2026, $2.1 billion in Q4 2025, and $2.1 billion in Q3 2025.